Dedicated to discovery

in fracture fixation

About Us

We are engaged in the development of next generation therapeutics in osteoporosis. We have developed a regenerative medicine approach for fragility fractures,  improving implant anchorage leading to less fixation failures, re-operations, reduced societal costs and better quality of life.

The concept has been tested and proven in-vitro, in pre-clinical in-vivo studies, and in osteoporotic human bone explants, and is currently undergoing a feasibility study.

biology, research, laboratory-220005.jpg



We have developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures.

Play Video


Moroxite F appoints Johan Tinnerholm as the CEO

Moroxite F announces the appointment of Johan Tinnerholm    as the CEO. Johan has a broad experience from leading roles at stock listed companies like Agilit Holding AB, Curando Nordic and Safeture.

Moroxite F raises external funding

Moroxite F has raised its first external capital of SEK 10 millon, of which 6 million from Fåhraeus Startup and Growth and 4 million from ALMI Invest.